# Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

> **NCT06509945** · NA · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 50 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **OTHER:** allogeneic peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT06509945
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509945, "Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06509945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*